Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Exclusion Criteria

• •Predominantly squamous cell histology NSCLC.
• •History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
• •Grade ≥2 peripheral neuropathy.
• •History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
• •Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
• •Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.
• •Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
• •Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
• •Received radiation therapy to the lung that is \>30 Gray within 6 months of the first dose of study intervention.
• •Known active central nervous system metastases and/or carcinomatous meningitis.
• •Active infection requiring systemic therapy.
• •History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
• •HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
• •Concurrent active HBV and HCV infection.
• •History of allogeneic tissue/solid organ transplant.
• •Participants who have not adequately recovered from major surgery or have ongoing surgical complications.